Contact Us

Empowering Next Gen Infectious Disease & Vaccine Development

Clinical studies generate a limited number of high‑value biological samples. To maximise their impact, laboratories need technologies that deliver more insight from less material—without compromising data quality or sensitivity. The QX700S Digital Droplet PCR Platform (ddPCR) offers an advanced solution for high‑precision measurement, mutation verification, and sensitive target detection.

The Challenge

In clinical research, every sample counts. Traditional molecular methods may struggle when sample volume is limited, rare mutations require high‑sensitivity detection, reproducibility is vital, and rapid turnaround is essential.

Our Solution: QX700S Digital PCR Platform (ddPCR)

hVIVO is the first global clinical trials laboratory to implement the QX700S platform in partnership with Bio‑Rad, reinforcing leadership in molecular innovation. Key features include 7‑colour multiplexing supporting up to 21 targets, ultra‑low sample volume requirements, high sensitivity for rare event detection, and high‑throughput automation.


Impact on Clinical Development

ddPCR plays a key part alongside Next Generation Sequencing (NGS) to deliver complementary, highly sensitive detection and quantification. It accelerates development timelines, increases confidence in early‑stage decisions, and supports precise quantification for vaccines, therapeutics, and gene therapies.

Key Benefits:

  • More insight from a single sample
  • High sensitivity for mutation verification
  • Rapid turnaround times
  • Reproducible, high‑quality data outputs
  • Future‑ready technology aligned with next‑generation molecular assays

Talk with our laboratory specialists

Contact hVIVO

Stay connected

Sign up to our emails and follow us on social media to keep up to date with hVIVO.

By clicking Sign Up you're confirming that you agree with our Privacy Policy.
chevron-downarrow-up